Trial · NCT02936752
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose of Entinostat Given in Combination With Pembrolizumab | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | Participants | ||
| Maximum Tolerated Dose of Entinostat Given in Combination With Pembrolizumab | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 2 | Participants | ||
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL1 | Complete Response (CR) | 0 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL2 | Complete Response (CR) | 0 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL1 | Partial Response (PR) | 0 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL2 | Partial Response (PR) | 0 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL1 | Stable Disease (SD) | 8 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL2 | Stable Disease (SD) | 3 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL1 | Progressive Disease (PD) | 5 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL2 | Progressive Disease (PD) | 0 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL1 | marrow Complete response (mCR) | 2 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL2 | marrow Complete response (mCR) | 0 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL1 | Not evaluable | 6 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL2 | Not evaluable | 3 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL1 | Hematologic Improvement (HI) Neutrophils | 1 | Participants | |
| Overall Response Rate (Complete Response [CR], Partial Response [PR], Hematologic Improvement [HI]) | Treatment (Entinostat, Pembrolizumab) DL2 | Hematologic Improvement (HI) Neutrophils | 0 | Participants | |
| Median Progression-free Survival | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 3.45 | Full Range 0.5 to 9.4 | months | |
| Median Progression-free Survival | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 3.68 | Full Range 0.9 to 8.8 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02936752/results